• Japanese
  • Korean
  • Chinese
Cover Image

Personalized Medicine - A Global Market Overview

Personalized Medicine can mean a lot of things to a lot of people. For some, it may relate to doctors having knowledge about their case history and the treatment received, which is a morale boosting factor, since everybody wants caregivers who can comprehend an individual's problems. The day is not very far when this level of personal or individual understanding between a patient and a doctor would be much deeper than hitherto anticipated. The coming decade is expected to witness an increase in the use of companion diagnostics and personalized medicines, with pricing incentives and efficiency improvement propelling the market. Current market leaders with diagnostic divisions focusing on biomarker identification would be at an advantage.

This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.

The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.

This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology. The report covers the brief business profiles of 56 key global players and 77 major players across the United States - 45; Europe - 24; and Rest of World - 8. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.

Table of Contents

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

  • 1.1. Product Outline
    • 1.1.1. Personalized Medicine's Influence on Large Scale Studies
    • 1.1.2. Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine
    • 1.1.3. Ramifications of Personalized Medicine for Healthcare Systems
      • 1.1.3.1. Pharmaceutical Industry
      • 1.1.3.2. Diagnostics Industry
      • 1.1.3.3. Insurers
      • 1.1.3.4. Physicians
      • 1.1.3.5. Government Agencies
      • 1.1.3.6. Patients
    • 1.1.4. Analysis of Personalized Medicine by Segment
      • 1.1.4.1. Targeted Biologics
        • 1.1.4.1.1. Overview
        • 1.1.4.1.2. Targeted Biologics for Breast Cancer: An Illustration
          • 1.1.4.1.2.1. Targeted Biologic Therapy for Breast Cancer
      • 1.1.4.2. Proteomics & Genomics
        • 1.1.4.2.1. Proteomics
          • 1.1.4.2.1.1. A Complex Problem
          • 1.1.4.2.1.2. Post-Translational Modifications
          • 1.1.4.2.1.3. Phosphorylation
          • 1.1.4.2.1.4. Ubiquitination
          • 1.1.4.2.1.5. Other Modifications
          • 1.1.4.2.1.6. Inadequacies in Proteomics Studies
          • 1.1.4.2.1.7. Proteomics in Practical Applications
        • 1.1.4.2.2. Genomics
          • 1.1.4.2.2.1. Pharmacogenomics
      • 1.1.4.3. Genetically Modified (GM) Products
        • 1.1.4.3.1. The Genetic Engineering Process
          • 1.1.4.3.1.1. Applications of Genetic Engineering
      • 1.1.4.4. Wellness & Disease Management
        • 1.1.4.4.1. Wellness Defined
          • 1.1.4.4.1.1. The Ten Dimensions of Wellness
        • 1.1.4.4.2. Disease Management Defined
      • 1.1.4.5. Molecular Diagnostic Technologies
        • 1.1.4.5.1. DNA Sequencing
        • 1.1.4.5.2. Biochips and Microarrays
          • 1.1.4.5.2.1. Personalized Medicine Development Using DNA Biochip Technology
          • 1.1.4.5.2.2. Protein Biochips' Role in Personalized Medicine
        • 1.1.4.5.3. Cytogenetics
          • 1.1.4.5.3.1. Personalized Medicine Based on Molecular Cytogenetics
          • 1.1.4.5.3.2. Personalized Medicine Based on Cytomics
        • 1.1.4.5.4. Single Nucleotide Polymorphism (SNP) Genotyping
          • 1.1.4.5.4.1. Technologies for SNP Analysis
          • 1.1.4.5.4.2. Applications of SNPs Pertinent to Personalized Medicine
        • 1.1.4.5.5. Haplotyping
          • 1.1.4.5.5.1. HapMap Project
          • 1.1.4.5.5.2. HapMap for Predicting Drug Response
        • 1.1.4.5.6. Application of Proteomics in Molecular Diagnosis
          • 1.1.4.5.6.1. Proteomic and Genomic Approaches in Personalized Medicine Compared
        • 1.1.4.5.7. Gene Expression Profiling
        • 1.1.4.5.8. Personalized Medicine and Molecular Imaging
        • 1.1.4.5.9. Diagnostics Based On Glycomics
        • 1.1.4.5.10. Combining Diagnostics and Therapeutics
        • 1.1.4.5.11. Point-Of-Care (POC) Diagnosis
          • 1.1.4.5.11.1. Point-of-Care Diagnosis of Infections
          • 1.1.4.5.11.2. Positives and Negatives of Point-of-Care Diagnosis
        • 1.1.4.5.12. Genetic Testing For Disease Predisposition
    • 1.1.5. Analysis of Personalized Medicine by Technology
      • 1.1.5.1. Pharmacogenomics
        • 1.1.5.1.1. Drug Metabolism
        • 1.1.5.1.2. Applications
      • 1.1.5.2. Point-of-Care Testing
        • 1.1.5.2.1. Tests that are Most Apt for Specific Scenarios
          • 1.1.5.2.1.1. Primary Care
          • 1.1.5.2.1.2. Emergency Room
          • 1.1.5.2.1.3. Intensive Care
        • 1.1.5.2.2. Advantages
      • 1.1.5.3. Stem Cell Therapy
        • 1.1.5.3.1. Treatment with Stem Cells
        • 1.1.5.3.2. Current Therapies
        • 1.1.5.3.3. Future Treatments
      • 1.1.5.4. Pharmacoproteomics
      • 1.1.5.5. Pharmacogenetics
        • 1.1.5.5.1. Prediction of Drug-Drug Interactions
        • 1.1.5.5.2. Integration of Pharmacogenetics with the Healthcare System
        • 1.1.5.5.3. Pharmacogenetic Tests
        • 1.1.5.5.4. Currently Used Tests
      • 1.1.5.6. Other Personalized Medicine Technologies
        • 1.1.5.6.1. Biochips
          • 1.1.5.6.1.1. Fabrication of Microarrays
          • 1.1.5.6.1.2. Protein Biochip Array and Other Microarray Technologies
          • 1.1.5.6.1.3. Biochips Applications: Ranging from Diagnostics to Personalized Medicine
        • 1.1.5.6.2. Genetic Screening
          • 1.1.5.6.2.1. Basic Screening
          • 1.1.5.6.2.2. Screening Variations
          • 1.1.5.6.2.3. Genetic Screening: Ethical Issues and Concerns
        • 1.1.5.6.3. Metabolomics
        • 1.1.5.6.4. Molecular Diagnostics
          • 1.1.5.6.4.1. Molecular Diagnostics for Personalized Medicine
        • 1.1.5.6.5. Pharmacodynamics
        • 1.1.5.6.6. Pharmacokinetics
        • 1.1.5.6.7. SNP Genotyping
          • 1.1.5.6.7.1. Core Labs
          • 1.1.5.6.7.2. Hybridization-Based Methods
          • 1.1.5.6.7.3. Enzyme-Based Methods
          • 1.1.5.6.7.4. Other Post-Amplification Methods Based on Physical Properties of DNA
    • 1.1.6. The Rationale Behind Personalized Medicine: “One Size no Longer Fits All”
    • 1.1.7. The Human Genome: What is It?

2. KEY MARKET TRENDS

  • Combating Melanoma and Lung Cancer Facilitated Using Novel Personalized Drugs
  • Personalized Medicine for Heart Patients Promised by University of Florida Academic Health Center
  • Personalized Medicine Integrated with Biosensors
  • Decade-Long Penn Medicine Study of HIV Patients Demonstrates Safety of Genetically Modified T Cell Therapy
  • Managing Infectious Diseases Using Point-of-Care Personalized Medicine Molecular Diagnostic Technologies
    • Introduction
    • Personalized Medicine and Infectious Diseases: An Unlikely Combination?
  • Universities to be Commended for Bringing Personalized Medicine to Patient Care
  • Nuclear Imaging Market to be Boosted through a Trend towards Personalized Medicine
  • Personalized Medicine for Lung Cancer Makes Progress
    • Micro RNA Denotes Response to Chemoprevention
    • Shorter Survival Predicted from RRM
    • Differentiating Tumor Types through Epigenetic Clues
  • Pharmaceutical and Diagnostic Company Business Models being Challenged by Personalized Medicine
  • Personalized Medicine and Pharmacogenomics: Single Nucleotide Polymorphisms (SNPs) Role in Drug Therapy
    • Personalization of Medicine and the Role of SNPs
    • The Arrival of Pharmacogenetics and Illustrations of SNPs in Personalized Medicine
    • Personalized Medicine's Drawbacks in the Context of Genetic Discrimination
  • Personalized Medicine's Promise of Offering the Future Now
    • The Course of Advancements in Cancers
    • Live Healthy to Make a Difference
  • Personalized Medicine in Cancer Hits a Roadblock
  • Implications of Personalized Medicine for Pharmaceutical Manufacturers and Drug Development
    • Implications of Personalized Medicine
    • What Should Drug Developers Do
  • Is Drug Safety Capable of Being Improved through Personalized Medicine?
  • Personalized Medicine: A SWOT Analysis for Pharmacists
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Genetic Testing for Identifying and Treating Specific Disorders
  • The Scientific and Commercial Facets of Personalized Medicine
  • Prevention and Treatment of Diabetes with Personalized Medicine
  • Medical Informatics and Personalized Medicine
  • Personalized Medicine for Treating Asthma
  • Personalized Medicine and Systems Engineering
  • The Evolving Role of CROs in Personalized Medicine
  • Personalized Medicine Being Guided by Stem Cell Therapies
  • Device Manufacturers Offered Better Prospects from the Trend Towards Personalized Medicine

3. KEY GLOBAL PLAYERS

4. KEY BUSINESS TRENDS

  • Lilly Partners with PrimeraDX for Novel Personalized Therapeutics
  • Sanofi Joins with Joslin Diabetes Center to Develop New Drugs
  • New Personalized Medicine Center to be Opened by PerkinElmer
  • Roche Signs Strategic Pact with Med Fusion
  • Agendia Introduces a New 18-Gene Expression Signature
  • Affymetrix Enters Research Collaboration with MGH
  • Affymetrix Signs Research Contract with Leica
  • Millennium Labs Launches Innovative Pharmacogenetic Test
  • Genedata Expressionist Opted for by Takeda
  • Boehringer Ingelheim and Healthrageous in an Agreement
  • Merck KGaA and MDxHealth Form Collaboration
  • FDA Approves Colorectal Cancer Companion Diagnostic from Qiagen
  • KineMed Collaborates with GSK for Biomarker Discovery
  • bioTheranostics Expands PRÉCIS Biomarker Profiles
  • Quest Introduces New Molecular Test Panel
  • Biocartis Collaborates with Philips and Wellcome Trust
  • Agreement Signed between Immunexpress, Debiopharm, and Biocartis
  • Lab21 Sings Pact with Major Pharma Company to Develop Companion Diagnostic Assay
  • Clarient Acquires IP Rights for Developing ALK Biomarker Genetic Tests from Insight Genetics
  • Exosome Signs and Life Technologies Sign an Agreement
  • NextGen Commercializes Assay for New Diagnostics Biomarkers in Brain Disorders
  • Sanofi Collaborates with Joslin Diabetes Center
  • Perjeta™(Pertuzumab) for People with HER2-Positive Metastatic Breast Cancer Granted FDA Approval
  • Software Re-enlisted by Roche for Personalized Medicine Research
  • Teva All Set to Enter Personalized Medicine Field
  • Personalized Medicine Test for ADHD Launched by AssureRx Health
  • XALKORI® Launched in Canada by Pfizer
  • Abbott Acquires License for Novel Biomarkers from Stanford
  • GE Bags SeqWright
  • PerkinElmer Unveils HER2Sense for Breast Cancer Research
  • Celgene Files FDA Application for Multiple Myeloma Drug
  • Takeda and Metabolon in a Partnership
  • Biomed Analytics Platform Tested by IBM in Association with Italian Institute
  • Abbott Joins Hands with Merck to Develop Companion Diagnostic Test
  • Chronix Biomedical Inaugurates State-of-the-Art Mass Sequencing Laboratory for Personal Biomarkers
  • Personalized Medicine Offered by IBM Genomic Analytics Platform
  • Clinical Genomics Centre Launched in USA by Lab21 and ITOR
  • GlaxoSmithKline and Epistem in an Agreement
  • Online Personalized Medicine Portal Launched by Cepmed
  • Dako Partners with Amgen to Develop Companion Diagnostic Test for Investigational Cancer Therapy
  • Personalized Medicine Partnership of Florida is to be Created
  • China's SFDA Approves First Microarray Instrument GCS 3000Dx v.2
  • Health Canada Approves First and Only Personalized Treatment for Deadliest Form of Skin Cancer
  • New Personalized Medicine Institute Launched by Moffitt Cancer Centre
  • Roche Bags EU Approval for Zelboraf
  • Amgen and Dako in an Alliance for Developing New Diagnostic Test for Cancer Therapy
  • Siemens Enters Personalized Medicine Field
  • Ventana Medical and Bayer Joins Forces to Develop Companion Diagnostic Test
  • AssureRx Launches GeneSightRx 1.8
  • bioTheranostics Unveils Precision Medicine Biomarkers
  • Identification of DNA Variants for Personalized Medicine Research by Ingenuity
  • Genzyme and Veracyte in an Agreement
  • OvaGene Joins Forces with Moffitt Cancer Center
  • GlaxoSmithKline and Abbott in Agreement to Expand Personalized Medicine for Cancer Diagnostic
  • Siemens and Illumina in a Partnership
  • Pfizer's Xalkori and Abbott Demonstrate a Bright Scope in Personalized Medicine, Companion Diagnostics
  • GNS Healthcare Collaborates with Bristol-Myers Squibb
  • Genetically Modified Human Cell Lines for Breast Cancer Research from Sigma® Life Science
  • Coriell Partners with IBM
  • QIAGEN Agrees to Acquire 61% Stake in Ipsogen
  • Joint Development of Biomarkers in Oncology by Roche and Evotec
  • Innovative COX-2 Probe Launched by Caliper Life Sciences
  • Caliper and Catholic Health Initiatives form Oncology Research Collaboration
  • Novel Patient-Specific Drug Targets Identified by GNS Healthcare and Biogen
  • Daiichi Sankyo Takes Over Plexxikon
  • Collaboration between Ipsen SA and BioMerieux SA in Personalized Medicine
  • AstraZeneca and HealthCore Form Collaboration
  • Minority Stake in Alacris Theranostics acquired by QIAGEN
  • GenomeQuest and Ingenuity Systems Form Partnership
  • Veridex and Massachusetts General Hospital Form Collaboration
  • Development of Personalized Medicine Further Accelerated with the Partnership between Dako and Quintiles
  • First Pharmacogenomics Test Launched by Luminex Corp. for Personalized Medicine
  • Integration of Software between Ingenuity Systems and TransMed to Support Personalized Medicine Research
  • Advancement of Personalized Medicine with the Launch of New Multiplex Tissue Biomarker Technology
  • Personalized Medicine Brought to Market by Iris Biotechnologies

5. GLOBAL MARKET OVERVIEW

  • 5.1. Market Overview by Product Type
  • 5.2. Market Overview by Technology
  • 5.3. Personalized Medicine Product Type Overview by Global Region
    • 5.3.1. Targeted Biologics
    • 5.3.2. Proteomics & Genomics
    • 5.3.3. Genetically Modified (GM) Products
    • 5.3.4. Wellness & Disease Management
    • 5.3.5. Other Molecular Diagnostic Products
    • 5.3.6. Self/Other Diagnostics
  • 5.4. Personalized Medicine Technology Overview by Global Region
    • 5.4.1. Pharmacogenomics
    • 5.4.2. Point-of-Care Testing
    • 5.4.3. Stem Cell Therapy
    • 5.4.4. Pharmacoproteomics
    • 5.4.5. Pharmacogenetics
    • 5.4.6. Other Personalized Medicine Technologies

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES

  • 1.1. Market Overview by Product Type
  • 1.2. Market Overview by Technology
  • 1.3. Major Market Players
    • Abbott Laboratories, Inc.
    • Abbott Molecular Inc
    • Affymetrix, Inc.
    • Agilent Technologies, Inc.
    • Amgen, Inc.
    • Asuragen, Inc.
    • Baxter International Inc.
    • Beckman Coulter Genomics Inc.
    • Beckman Coulter, Inc.
    • BG Medicine, Inc.
    • Biogen Idec
    • Bristol-Myers Squibb Company
    • Caliper Life Sciences, Inc.
    • Celera Corporation
    • Celgene Corporation
    • Celldex Therapeutics
    • Cepheid
    • DNA Direct, Inc.
    • Eli Lilly and Company
    • Exact Sciences Corp.
    • Exagen Diagnostics, Inc.
    • Gene Logic
    • Genelex Corporation
    • Genentech, Inc.
    • Genomic Health Inc
    • Gen-Probe Incorporated
    • Genzyme Corporation
    • HistoRx, Inc.
    • Hologic Inc
    • Illumina, Inc.
    • Ingenuity Systems, Inc.
    • Johnson & Johnson
    • Laboratory Corporation of America (LABCORP)
    • Life Technologies Corporation
    • Luminex Corporation
    • Millennium Laboratories
    • Myriad Genetics, Inc.
    • PerkinElmer, Inc.
    • Pfizer Inc
    • Promega Corporation
    • Roche Diagnostics Corporation
    • Siemens Healthcare Diagnostics Inc.
    • Sigma-Aldrich Corporation
    • Thermo Fisher Scientific Inc
    • Ventana Medical Systems, Inc.

2. EUROPE

  • 2.1. Market Overview by Product Type
  • 2.2. Market Overview by Technology
  • 2.3. Major Market Players
    • Agendia B.V. (The Netherlands)
    • AstraZeneca PLC (United Kingdom)
    • Bayer AG (Germany)
    • Bayer Healthcare AG (Germany)
    • Bayer Healthcare Pharmaceuticals (Germany)
    • Biocartis NV (Belgium)
    • Biocartis SA (Switzerland)
    • bioMérieux SA (France)
    • Boehringer Ingelheim GmbH (Germany)
    • Cytolon AG (Germany)
    • Dako A/S (Denmark)
    • Decode Genetics (Iceland)
    • Epistem Holdings PLC (United Kingdom)
    • Evotec AG (Germany)
    • GE Healthcare Ltd. (United Kingdom)
    • GlaxoSmithKline, PLC (United Kingdom)
    • Merck KGaA (Germany)
    • Novartis AG (Switzerland)
    • Qiagen N.V. (The Netherlands)
    • Roche Holding Ltd. (Switzerland)
    • Sanofi (France)
    • Siemens AG (Germany)
    • Siemens Healthcare (Germany)
    • The European Personalised Medicine Association (EPEMED) (Luxembourg)

3. REST OF WORLD

  • 3.1. Market Overview by Product Type
  • 3.2. Market Overview by Technology
  • 3.3. Major Market Players
    • Astellas Pharma Inc. (Japan)
    • Cepmed (Canada)
    • Daiichi Sankyo Company Limited (Japan)
    • DNA Genotek Inc. (Canada)
    • Mitsubishi Tanabe Pharma Corporation (Japan)
    • Rosetta Genomics Ltd. (Israel)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Takeda Pharmaceutical Company Limited (Japan)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA

  • 1.1. Canada
  • 1.2. United States

2. EUROPE

  • 2.1. Austria
  • 2.2. Belgium
  • 2.3. Denmark
  • 2.4. France
  • 2.5. Germany
  • 2.6. Iceland
  • 2.7. Ireland
  • 2.8. Italy
  • 2.9. Luxembourg
  • 2.10. Spain
  • 2.11. Switzerland
  • 2.12. The Netherlands
  • 2.13. United Kingdom

3. ASIA-PACIFIC

  • 3.1. Australia
  • 3.2. China
  • 3.3. Hong Kong
  • 3.4. Japan
  • 3.5. New Zealand
  • 3.6. South Korea
  • 3.7. Taiwan

4. REST OF WORLD

  • 4.1. Israel

5. RESEARCH & EDUCATIONAL INSTITUTIONS

PART D: ANNEXURE

1. RESEARCH METHODOLOGY

2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

  • Chart 1: Global Personalized Medicine Market Analysis (2008-2018) in USD Million
  • Chart 2: Global Personalized Medicine Market Analysis (2008-2018) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million
  • Chart 3: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics
  • Chart 4: Global Personalized Medicine Market Analysis (2008-2018) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million
  • Chart 5: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies
  • Chart 6: Global Market Analysis of Targeted Biologics in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 7: Glance at 2008, 2013 and 2018 Global Market Share (%) of Targeted Biologics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 8: Global Market Analysis of Proteomics & Genomics in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 9: Glance at 2008, 2013 and 2018 Global Market Share (%) of Proteomics & Genomics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 10: Global Market Analysis of Genetically Modified (GM) Products in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 11: Glance at 2008, 2013 and 2018 Global Market Share (%) of Genetically Modified (GM) Products in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 12: Global Market Analysis of Wellness & Disease Management in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 13: Glance at 2008, 2013 and 2018 Global Market Share (%) of Wellness & Disease Management in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 14: Global Market Analysis of Other Molecular Diagnostics in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 15: Glance at 2008, 2013 and 2018 Global Market Share (%) of Other Molecular Diagnostics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 16: Global Market Analysis of Self/Other Diagnostics in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 17: Glance at 2008, 2013 and 2018 Global Market Share (%) of Self/Other Diagnostics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 18: Global Market Analysis of Pharmacogenomics in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 19: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacogenomics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 20: Global Market Analysis of Point-of-Care Testing in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 21: Glance at 2008, 2013 and 2018 Global Market Share (%) of Point-of-Care Testing in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 22: Global Market Analysis of Stem Cell Therapy in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 23: Glance at 2008, 2013 and 2018 Global Market Share (%) of Stem Cell Therapy in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 24: Global Market Analysis of Pharmacoproteomics in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 25: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacoproteomics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 26: Global Market Analysis of Pharmacogenetics in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 27: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacogenetics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
  • Chart 28: Global Market Analysis of Other Personalized Medicine Technologies (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 29: Glance at 2008, 2013 and 2018 Global Market Share (%) of Other Personalized Medicine Technologies by Geographic Region - United States, Europe and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

  • Chart 30: Global Personalized Medicine Market Analysis (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
  • Chart 31: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Geographic Region - United States, Europe and Rest of World

REGIONAL MARKET OVERVIEW

THE UNITED STATES

  • Chart 32: United States Personalized Medicine Market Analysis (2008-2018) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million
  • Chart 33: Glance at 2008, 2013 and 2018 United States Personalized Medicine Market Share (%) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics
  • Chart 34: United States Personalized Medicine Market Analysis (2008-2018) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million
  • Chart 35: Glance at 2008, 2013 and 2018 United States Personalized Medicine Market Share (%) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

EUROPE

  • Chart 36: European Personalized Medicine Market Analysis (2008-2018) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million
  • Chart 37: Glance at 2008, 2013 and 2018 European Personalized Medicine Market Share (%) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics
  • Chart 38: European Personalized Medicine Market Analysis (2008-2018) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million
  • Chart 39: Glance at 2008, 2013 and 2018 European Personalized Medicine Market Share (%) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

REST OF WORLD

  • Chart 40: Rest of World Personalized Medicine Market Analysis (2008-2018) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million
  • Chart 41: Glance at 2008, 2013 and 2018 Rest of World Personalized Medicine Market Share (%) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics
  • Chart 42: Rest of World Personalized Medicine Market Analysis (2008-2018) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million
  • Chart 43: Glance at 2008, 2013 and 2018 Rest of World Personalized Medicine Market Share (%) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies
Show More
RELATED REPORTS
* Personalized Medicine Partnering Terms and Agreements
  • Published:
  • Apr 02, 2014
  • USD 3295

* Personalized Medicine - scientific & commercial aspects
  • Published:
  • Mar 01, 2014
  • USD 5000

* Personalized Medicine in Oncology Partnering Terms and Agreements
  • Published:
  • Jan 10, 2014
  • USD 2995
  • 833 Pages

* Personalized Medicine and Companion Diagnostic Market 2014- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
  • Published:
  • Jan 03, 2014
  • USD 3660
  • 224 Pages

* Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018
  • Published:
  • Sep 30, 2013
  • USD 4650
  • 173 Pages

* Molecular Cytogenetics Market (Technologies: FISH and aCGH; Applications: Genetic Disorders, Cancer and Personalized Medicine) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
  • Published:
  • Aug 21, 2013
  • USD 4595
  • 96 Pages

* Global Personalized Medicine Diagnostics Market 2012-2016
  • Published:
  • Jul 26, 2013
  • USD 3000
  • 111 Pages

* Future Prospects of Global Personalized Medicine Market 2012-2016
  • Published:
  • Jul 05, 2013
  • USD 2500
  • 60 Pages

* Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017
  • Published:
  • Jul 01, 2013
  • USD 4650
  • 350 Pages

* Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)
  • Published:
  • Jun 13, 2013
  • USD 1400
  • 173 Pages

Browse more Personalized Medicine Market Research Reports

Pricing
Get Notified
Email me when related reports are published